Aleta Biotherapeutics

Natick, United States

Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.

$13.7M raised

Jul 2021

Series A

Biotechnology Health Care Therapeutics

Top Investors

Advent Life Sciences Viva BioInnovator

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Aleta Biotherapeutics

How much funding has Aleta Biotherapeutics raised?

Aleta Biotherapeutics has raised $13.7M in total funding. The most recent round was Series A. The last funding was announced in July 2021.

Who are Aleta Biotherapeutics's investors?

Aleta Biotherapeutics's investors include Advent Life Sciences, Viva BioInnovator.

Where is Aleta Biotherapeutics headquartered?

Aleta Biotherapeutics is headquartered in Natick, United States.

What does Aleta Biotherapeutics do?

Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.

What stage is Aleta Biotherapeutics at?

Aleta Biotherapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 16, 2021.

MLA

"Aleta Biotherapeutics — Funding & Investors." VCBacked, July 16, 2021, https://www.vcbacked.co/company/aleta-biotherapeutics. Accessed July 2, 2026.

APA

VCBacked. (2021). Aleta Biotherapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/aleta-biotherapeutics

Wikipedia (cite web)

{{cite web |title=Aleta Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aleta-biotherapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 16, 2021.

Similar Companies in Biotechnology

View all

Renaissance BioScience

Vancouver$599K

Allterum Therapeutics

Advanced Microbiome Interventions

Amsterdam$300K